Asia Fresh News

Asia Fresh Stories

Archive for November 21st, 2014

Pacquiao and Algieri Ready to Face Off Sunday at The Venetian Macao for Clash in Cotai II

leave a comment »

-Multi-bout boxing event kicks off 8 a.m. at Cotai Arena

MACAO /PRNewswire/ — Sands China Ltd. and Top Rank held a press conference Wednesday at The Venetian® Macao, featuring the exciting superstar boxers of the upcoming Nov. 23 Clash in Cotai II main event  Fighter of the Decade Congressman MANNY “Pacman” PACQUIAO, boxing’s only eight-division world champion, and undefeated World Boxing Organization (WBO) junior welterweight champion CHRIS ALGIERI.

The two superstar boxers – Fighter of the Decade Congressman Manny “Pacman” Pacquiao (second from left) and undefeated World Boxing Organization (WBO) junior welterweight champion Chris Algieri (second from right) of Sunday’s Clash in Cotai II attend a press conference Wednesday at The Venetian Macao. The multi-bout event kicks off at 8 a.m. Sunday at the Cotai Arena, with a limited number of tickets still available via Cotai Ticketing.
The two superstar boxers – Fighter of the Decade Congressman Manny “Pacman” Pacquiao (second from left) and undefeated World Boxing Organization (WBO) junior welterweight champion Chris Algieri (second from right) of Sunday’s Clash in Cotai II attend a press conference Wednesday at The Venetian Macao. The multi-bout event kicks off at 8 a.m. Sunday at the Cotai Arena, with a limited number of tickets still available via Cotai Ticketing.

“Sands China and Top Rank are delivering another incredible line-up of sports entertainment with Clash in Cotai II,” said Edward Tracy, President and Chief Executive Officer of Sands China Ltd. “The world will be watching this Sunday, and we are certain this event will be shining a global spotlight on Macao, and that it provides a platform for some of Asia’s rising boxing stars to further develop their professional careers.”

“Pacquiao vs. Algieri has captured the world’s imagination,” said Hall of Fame promoter Bob Arum. “You cannot find two better stories in boxing, much less sports, than what we are presenting on Sunday. And I think it is only fitting that The Venetian Macao, which has become one of boxing’s biggest international stages, hosts this world championship event.”

Clash in Cotai II is the latest offering of Sands China’s multi-tiered entertainment strategy, which brings the world’s biggest and best superstar entertainment to Macao, raising the profile of the city as a world centre of tourism and leisure, and one of the region’s premier destinations for entertainment. International superstars expected to be in the Cotai Arena audience watching the action live include Sylvester Stallone, Arnold Schwarzenegger, Jessica Jung, Shannon Lee, Melody Thornton and several others.

Pacquiao (56-4-3), the Filipino icon, defends his WBO welterweight title against Algieri (20-0), the scholar-fighter,Sunday, November 23, at The Venetian® Macao’s Cotai Arena.  Promoted by Top Rank® and Sands China Ltd., in association with MP Promotions, Joe DeGuardia’s Star Boxing, Banner Promotions and Tecate, the Pacquiao vs. Algieri world welterweight championship event will be produced and distributed live by HBO Pay-Per-View®.

Six different nations will be represented by the eight fighters on the live pay-per-view undercard. Top-five contenders ZOU SHIMING, of China, and KWANPICHIT ONESONGCHAIGYM, of Thailand, will be battling in a 12-round WBO flyweight world title elimination bout  giving the winner an automatic shot at a world title. Ukrainian VASYL LOMACHENKO will make the first defence of his WBO featherweight title against No. 1 contender and mandatory challenger CHONLATARN PIRIYAPINYO of Thailand.  JESSIE VARGAS, of Las Vegas, Nevada, will be defending his WBA super lightweight title against former world champion ANTONIO DEMARCO of Mexico. These six gladiators boast a combined record of 142-5-3 (79 KOs), a winning percentage of 95 per cent and a victory by knockout ratio of 56 per cent.

Also fighting will be Hong Kong’s REX “THE WONDER KID” TSO and “THE MACAO KID” NG KUOK KUN, each looking to extend their undefeated records. Tso (14-0, 9 KOs), of Hong Kong will battle ESPINOS SABU (11-2-1, 5 KOs), from Manado, Indonesia, in an eight-round super flyweight bout. Ng (5-0, 2 KOs), from Macao, will take onSTEPHEN ATTARD (4-0-2, 1 KO), from Preston, Australia, in a six-round super welterweight fight.

See appendix that follows for fighter profiles for key fights

A limited number of tickets for Clash in Cotai II are still available via Cotai Ticketing™. The multi-bout event kicks off Nov. 23, 2014 at 8 a.m. at the Cotai Arena. For details, visit www.venetianmacao.com/macau-entertainment/clash-in-cotai-ii.html.

For fight updates go to www.toprank.com, or www.hbo.com/boxing, on Facebook at facebook.com/trboxing,facebparook.com/trboxeo, or facebook.com/hboboxing, and on Twitter at twitter.com/trboxing, twitter.com/trboxeo, or twitter.com/hboboxing. Use the Hashtag #PacAlgieri to join the conversation on Twitter.

Bouts and times subject to change

Entertainment at Sands China Ltd. Properties

Sands China Ltd. has as a clear vision to establish Macao as Asia’s top entertainment destination.

The 15,000-seat Cotai Arena is the only venue in Asia ranked in Pollstar’s Top 100 Worldwide Arena Venues based on ticket sales. It is the top entertainment destination in southern China, hosting the world’s and the region’s biggest names in music, sports and awards shows. Superstars frequently choose the venue as the starting point of their Asian tours.

The 1800-seat, multi-purpose Venetian Theatre is one of the most luxurious entertainment venues in greaterChina. Featuring ushers in black-tie, champagne service, gourmet food and beverage items and other unique, premium amenities, it offers an intimate, luxurious and exclusive venue experience. The Venetian Theatre is playing a key role in bringing the best in international and Chinese entertainment to Macao, with a luxury theatre experience like no other in the region.

The 650-seat Sands Theatre regularly features internationally-renowned singers, performers and artists of the highest calibre. From traditional Chinese-costumed dancers to modern performances, and from singing troupes to contemporary bands, everything from Western rock to Cantonese pop is covered.

With an unbeatable diversity, the entertainment offering of Sands China Ltd. is ushering in a new era of entertainment in Macao.

For information about upcoming shows and events, visit www.venetianmacao.com/entertainment.html.

About The Venetian® Macao

Opened in 2007, The Venetian® Macao is Macao’s first integrated resort featuring stunning replicas of the famous canals and architectural icons of Venice, Italy. The Venetian Macao features 3,000 suites, 1.2 million square feet (111,000 square metres) of convention and meeting facilities as well as a 15,000-seat Cotai Arena designed for world-class sports events and electrifying entertainment. The Venetian Macao is also home to the unique, 1,800-seat luxury Venetian Theatre, hosting the best in international and Chinese entertainment; more than 30 renowned restaurants; TAIVEXMALO Day Hospital & Spa; the incredibly fun QUBE indoor playground and more than 300 retailers at Shoppes at Venetian. Outdoor recreation areas include swimming pools and cabanas and a mini-golf course.

For more information, please visit www.venetianmacao.com.

FOR ADDITIONAL INFORMATION (Media):

TOP RANK

Lee Samuels: +1-702-378-1083 / Lee@toprank.com
Ricardo Jimenez: +1-909-615-3436 / Ricardoej@aol.com
Fred Sternburg: +1-303-548-0707 / TooFred@aol.com
Ed Keenan: +1-609-399-1330 / Keenan@emcevents.com

VENETIAN MACAU LIMITED

Mabel Wu
Tel: +853-8118-2268
Email: mabel.wu@sands.com.mo

APPENDIX

Fighter profiles for key fights

Pacquiao vs. Algieri  12 Rounds  WBO World Welterweight Title

Manny Pacquiao (56-5-2, 38 KOs), the lone congressional representative from the Sarangani province in the Philippines (he was reelected to a second term, running unopposed last year), is the only fighter to win eight world titles in as many different weight divisions. A three-time Fighter of the Year and the Boxing Writers Association of America’s “Fighter of the Decade,” Pacquiao made his Cotai Arena debut last Nov. 24, pasting former world champion Brandon Rios with a unanimous decision beatdown. Pacquiao’s resumé features victories over present and future Hall of Famers, including Oscar De La Hoya, Ricky Hatton, Marco Antonio Barrera, Erik Morales, Miguel Cotto, Shane Mosley and Juan Manuel Marquez. From 2008 to 2010, five of his seven victories were world title victories in five different weight classes, from 130 to 154 pounds. No active boxer has sold more live tickets in the U.S. than Pacquiao, who is also credited with nearly 13 million domestic pay-per-view buys. He returns to the ring after avenging his controversial 2012 split decision loss to undefeated two-division world champion Timothy Bradley, Jr. on April 12. Pacquiao won a scintillating unanimous decision to regain the WBO welterweight crown back from Bradley.

Chris Algieri (20-0, 8 KOs), from Huntington, NY on Long Island, has become boxing’s No. 1 story, as well as being hailed as the 21st century real-life Rocky. Over the last 22 months, Algieri, a former kickboxing champion, has elevated himself from a prospect to a world-class contender to a world champion. After accumulating significant victories over top prospect Jose Alejo, former USBA champion Mike Arnaoutis, and highly-rated contender Emmanuel Taylor, Algieri, stepped up in his HBO debut and challenged WBO junior welterweight champion “The Siberian Rocky” Ruslan Provodnikov on June 14. Despite suffering two knockdowns in the first round which closed his swollen right eye, Algieri, who entered the fight as a 5-1 underdog, eschewed the natural instinct to panic and resolutely stuck to his game plan, expertly using his jab and supreme athletic ability to pick apart the defending champion to claim a split decision victory and the world title. The live, first-time airing of the fight on HBO averaged 1.1 million viewers placing it among the most-viewed fights on cable this year. In what could be a first for any professional boxer, Algieri used his purse from the Provodnikov bout to pay off his student loans. He is as much a scholar as he is a brawler. Algieri graduated from Stony Brook University with Honors in 2007 with a Bachelor of Science degree in Health Care Management and then went on to receive his Master’s degree in Clinical Nutrition from the New York Institute of Technology. He aspires to attend medical school.

Zou vs. Onesongchaigym  12 Rounds  Flyweight

Zou Shiming (5-0, 1 KO), from Guizhou, China, and trained by Hall of Famer Freddie Roach, returns to the ring fresh from his most impressive professional victory  a 10-round unanimous decision victory over Top-10 contender Luis De La Rosa to capture the vacant WBO International flyweight title. Stepping up to his first 10-round bout, Zou vs. De La Rosa took place on July 19 at the Cotai Arena and showed the world that Zou had developed into a world title contender. Zou is currently world-rated No. 4 by the WBA, No. 5 by the WBO and No. 7 by the WBC. He won his professional debut April 6, 2013 at Fists of Gold, via a dominant four-round unanimous decision over gritty Eleazar Valenzuela. He followed that up with six-round unanimous decision victories last year over Jesus Ortega and Juan Toscano July 27 at Fists of Gold II and November 24 at The Clash in Cotai, respectively, and celebrated his 2014 debut with his first professional knockout February 22 at Ring of Gold, stopping Yokthong Kokietgym in the seventh round. All of his professional bouts have taken place at the Cotai Arena. One of the most popular Olympic athletes in China, Zou was the world’s greatest amateur light flyweight, capturing gold medals in the World Amateur Championships in 2005, 2007 and 2011, along with gold medals in the 2008 and 2012 Summer Olympic Games. He also owns an Olympic bronze medal from the 2004 games, making him his nation’s first Olympic medallist in boxing as well as its first boxing gold medallist in the World Amateur Championships and the Olympics.

Kwanpichit Onesongchaigym (27-0-2, 12 KOs), of Buriram, Thailand, made his professional debut in 2010 and captured the WBO Oriental junior bantamweight title the following year knocking out Fredirex Rodriguez in the seventh round. After one successful defence he moved down one division where he captured the WBO Oriental flyweight title in 2012, which he has held for the past two years. Six of his last 10 victories have been by knockout, including his last one, a seventh-round TKO of Oscar Raknafa on June 6, to retain his title. Onesongchaigym is currently world-rated No. 3 by the WBO.

Lomachenko vs. Piriyapinyo  12 Rounds  WBO World Featherweight Title

The greatest amateur boxer of his era and arguably of all time, two-time Ukrainian Olympic gold medallist VasylLomachenko (2-1, 1 KO), of Odessa, captured the vacant WBO featherweight title on June 21, winning a scintillating majority decision over the previously unbeaten Gary Russell Jr. It was Lomachenko’s third professional bout, tying him with Thailand’s Saensak Muangsurin for fewest fights to win a world title. Muangsurin won a junior welterweight title in 1975, also in his third professional fight. Russell, a former U.S. Olympian, was totally blitzed by Lomachenko, battered around the ring throughout the fight. From the outset of his professional career, Lomachenko made it known that he was ready for the best in his division. He made his professional debut in 2013 knocking out the WBO’s No. 7-rated featherweight contender Jose Luis Ramirez (24-2-2, 15 KOs) in the fourth round of a bout that was scheduled for 10. Last March, in his second professional bout, he challenged WBO featherweight champion Orlando Salido, losing a split decision to the heavier defending champion whose title had been stripped because he could not make the weight limit. Lomachenko first gained international renown by winning gold medals in the 2008 Beijing Olympics and the 2012 London Games as a featherweight and a lightweight, respectively.

Chonlatarn Piriyapinyo (51-1, 33 KOs), made his pro debut in 2003 and captured the Asian featherweight title the following year in just his fifth professional bout. His only blemish is a world title decision loss to the legendary defending WBA featherweight champion Chris John in 2012. He enters his second world championship fight world-rated No. 1 and riding a two-year, eight-bout winning streak, including six victories by way of knockout.

Vargas vs. DeMarco — 12 Rounds — WBA World Super Lightweight Title

Jessie Vargas (25-0, 9 KOs), of Las Vegas, Nevada, will be fighting outside the U.S. for the first time in his professional career. He captured the WBA super lightweight title on the April 12 Pacquiao-Timothy Bradley Jr. world welterweight title rematch in Las Vegas, winning a unanimous decision over undefeated defending champion Khabib Allakhverdiev. It was a close and competitive fight that proved Vargas’ grit as he bit down hard during the championship rounds to pull away with the victory and the world championship belt. His impressive resume includes victories over former world champions Stevie Forbes and Vivian Harris and top contenders Josesito Lopez, Lucky Boy Omotoso, Ray Narh and Lanardo Tyner. In his last fight, on Aug. 2, Vargas successfully defended his title against undefeated contender Anton Novikov via a unanimous decision.

Antonio DeMarco (31-3-1, 23 KOs), of Tijuana, Mexico, captured the WBC lightweight championship crown on his second try, winning the vacant title with an 11th-round stoppage of top-rated contender Jorge Linares in 2011. DeMarco successfully defended the title twice during his one-year reign – both by knockout  against Miguel Roman and John Molina. Since moving up in weight, he has won three straight fights, with two of those victories coming by way of knockout. In his last fight, on Aug. 23, DeMarco won a 10-round unanimous decision overLandro Tyner.

Photo – http://photos.prnasia.com/prnh/20141120/8521406939

Source: Sands China Ltd.

Written by asiafreshnews

November 21, 2014 at 4:45 pm

Posted in Uncategorized

RS Components Augments Rapid-prototyping Product Portfolio with New Ultimaker 2 3D Printer

leave a comment »

-High resolution, high speed and most popular 3D desktop printer available targets wide range of users including engineers involved in rapid-prototyping and product concept development

HONG KONG, Nov. 20, 2014 /PRNewswire/ — RS Components (RS), the trading brand of Electrocomponents plc (LSE:ECM), the global distributor for engineers, has added to its growing range of rapid-prototyping machines with the Ultimaker 2 3D printer, recently voted Best Consumer Product 2014 at the London 3D Print Show Global Awards. This new desktop 3D printer employs fused filament fabrication (FFF) technology and targets electronics and mechanical engineers involved in design, prototyping and research and development, as well as enthusiasts and students.

Manufactured from premium parts and materials the latest version of the Ultimaker 3D printer, compared to its previous incarnation, now adds a heated bed, which smoothens the print output, allows for ABS material printing and also prevents warping. Claiming the highest speed and accuracy possible on any desktop 3D printer available today, the printer offers a print speed of up to 300mm/s and a layer resolution of only 20 microns or 0.02mm. In addition, it is available in a highly compact design with frame dimensions of 357 x 342 x 388mm (not including filament spool), offering an overall build volume of 230 x 225 x 205mm.

Other specifications include a nozzle diameter of 0.4mm, with the capability to handle a recommended filament diameter of 2.85mm. Operating temperatures of the print nozzle and heated bed are +180 – 260 degree Celsius and +50 – 100 degree Celsius, respectively.

Approximate usage cost, provided by the manufacturer Ultimaker, is EUR0.05 per cubic centimetre, combining both material and power cost. The use of FFF technology also allows the choice of a wide range of material filaments including popular choices such as PLA and ABS.

The printer also comes with a standalone SD-card for 3D-model file upload and Ultimaker’s Cura open-source software, which essentially slices a 3D-model into the requisite layers in preparation for printing. Cura was voted Best Consumer Software 2014 also at the London 3D Print Show Global Awards.

The Ultimaker 2 is available now from RS Components in EMEA and some Asia Pacific countries, and will be offered in Hong Kong at HKD 21250.

About RS Components

RS Components and Allied Electronics are the trading brands of Electrocomponents plc, the global distributor for engineers. With operations in 32 countries, we offer around 500,000 products through the internet, catalogues and at trade counters to over one million customers, shipping more than 44,000 parcels a day. Our products, sourced from 2,500 leading suppliers, include semiconductors, interconnect, passives and electromechanical, automation and control, electrical, test and measurement, tools and consumables.

Electrocomponents is listed on the London Stock Exchange and in the last financial year ended 31 March 2014had revenues of GBP 1.27bn.

For more information, please visit the website at www.rs-components.com.

RS Components
Tan Soo Chun
Public Relations Manager – Asia Pacific
Email: soochun.tan@rs-components.com
Telephone: +65-6391-5745

Edelman Public Relations (Singapore)
Yvette Yeo
Manager
Email: yvette.yeo@edelman.com
Telephone: +65-6347-2355

Further information is available via these links:

@RSElectronics; @alliedelec; @designsparkRS

RS Components on Linkedin
http://www.linkedin.com/company/rs-components

RS Components on Weibo
http://e.weibo.com/u/3206377000?type=0

Relevant Links:

Electrocomponents plc
www.electrocomponents.com

RS Components
http://www.rs-online.com/

DesignSpark
http://www.designspark.com

Logo – http://www.prnasia.com/sa/2011/05/04/20110504368830.jpg

Source: RS Components Singapore

Related stocks: LSE:ECM OTC-PINK:EENEY

Written by asiafreshnews

November 21, 2014 at 12:26 pm

New Data Suggest Patients’ Attitudes Should Not be Overlooked in Asthma Management

leave a comment »

-Identifying patient clusters, tailoring treatment plans proposed over “one size fits all” approach

SINGAPORE, Nov. 20, 2014 /PRNewswire/ — New data from a survey of over 2,000 asthma patients in Asia show that a better understanding of patients’ underlying attitudes may help clinicians improve the lives of the estimated 70 million sufferers[1] in the region.

Patients' Perceptions And Attitudes Are Linked With Sub-optimal Asthma Control In Asia.
Patients’ Perceptions And Attitudes Are Linked With Sub-optimal Asthma Control In Asia.

Findings from the REALISE™ Asia survey[2] were presented in three posters and three oral presentations at the 19th Congress of the Asian Pacific Society of Respirology in Bali, Indonesia from 13-16 November 2014.

Though 89% of respondents consider their asthma to be well-controlled, according to GINA clinical guidelines[3] (adhered to by medical practitioners) only 18% have their asthma under control. Even in those who think their asthma is controlled, indicators of poor control are high. Of respondents who indicate their asthma is under control, 61% say their daily activities are affected and 69% are woken up at night by asthma. Still, 78% said their asthma symptoms were not very serious.

The findings also highlight an aspect of asthma management that has gone mostly overlooked: patients’ beliefs about their condition and their definitions of controlled asthma. Patients’ understanding of ‘asthma control’ deviates from how guidelines have defined this treatment goal. Patients tend to relate asthma control more to managing attacks rather than preventing it.  Such understanding translates to a patient mindset that asthma lacks immediacy and relevance.

Additionally, the findings revealed:

  • 41% of respondents don’t see the need for taking their medication regularly when they’re not experiencing incapacitating symptoms or asthma attacks
  • Nearly half find using their inhaler a nuisance
  • Only 14% took their regular asthma medication daily, as it is prescribed, but 35% used their reliever medication more than 3 times in the past 7 days

The data point to opportunities for improving asthma management through interventions that might address the discrepancy between how patients perceive asthma control and actual control over their condition. Instead of the “one size fits all” approach to treatment, clinicians would do better to recognise and appreciate the role that patient attitudes play in asthma management. By matching patients to pre-defined “clusters”, the data suggest that clinicians can more easily develop tailored treatment plans to which patients might better adhere.

Cluster analysis of the REALISE™ Asia data[4] identified 5 segments in which patients with similar characteristics report comparable attitudes and subsequent treatment outcomes:

  • Well-Adjusted: Patients cope well with asthma, which has minimal impact on their daily lives. They are happy to go along with doctor’s advice and have lower stress levels.
  • Rejector: Patients refuse to accept the “asthma” label and are very independent in managing their condition. They are more inclined to deprioritise health and feel embarrassed using inhalers.
  • Lost: Patients have high levels of stress and anxiety about asthma, which has a large impact on their daily lives. They report problems with inhalers and have unanswered questions.
  • Endurer: Asthma doesn’t have a huge impact on their daily lives and they’re highly accepting of the “asthma” label, though they’re not very confident in managing their condition.
  • Worrier: Patients are highly impacted by asthma, are stressed and have the lowest confidence in managing their condition. They have the highest percentage of uncontrolled asthma and need emotional support.

Patients in the different clusters reported strikingly different outcomes, highlighting the effects that attitudes play in asthma management. Overall, Well-adjusted and Rejector clusters reported less healthcare resource utilisation compared with those in the Lost, Endurer and Worrier clusters.

Well-Adjusted patients (51%) are significantly more likely not to have used steroids in the past year, compared to the other clusters (27%). Over half of patients in the Lost and Worrier clusters required treatment at a hospital due to asthma hospitalised in the past year because of asthma, compared to only 17% in the Well-Adjusted cluster. 72% of those in the Worrier cluster reported using their reliever inhaler, compared to <50% for all other clusters.[5]

Uncontrolled asthma is associated with higher healthcare utilisation rates in Asia-Pacific countries[6] and these different healthcare utilisation rates reflects different levels of asthma control. The results also suggest that clusters may require different management approaches guided by the specific attitudes patients have about their condition.

Additional data to be presented sheds light on the importance of regularly monitoring patients’ inhaler techniques and how understanding country-by-country differences in perceived asthma control, asthma exacerbations, and use of asthma medications and inhalers can help clinicians to develop relevant interventions.

Hanlim Moon, Head of Medical Affairs Mundipharma, Asia Pacific, Latin America, Middle East and Africa, commented: “Findings from REALISE™ Asia are shedding light on new ways such as clustering patients by attitudes for clinicians to approach patients. The data support targeted approaches like tailored treatment plans to allow clinicians to work more closely with patient to improve asthma management and lower the burden of disease in Asia. Based on the findings, we at Mundipharma are able to better support our growing portfolio of respiratory medications with educational initiatives and informed outreach.”

Raman Singh, President, Asia Pacific, Latin America, Middle East, and Africa, commented:

“Asthma is a serious condition that often is not addressed seriously. The number of patients considered uncontrolled has remained stagnant for years, and insights from REALISE™ Asia are beginning to give us a better idea of why that is.”

The disconnect between patient-defined and clinician-defined control is a huge hurdle to overcome, but we believe that new approaches will allow clinicians to work more closely with patients to improve asthma management. Mundipharma’s support for REALISE™ Asia demonstrates our commitment to investing in research that supports both doctors and patients with the ultimate goal of reducing the burden of asthma on the more than 70 million Asians living with the debilitating condition.”

About REALISE™ Asia

The REALISE™ Asia, REcognise Asthma and LInk to Symptoms and Experiences, survey, sponsored by Mundipharma Pharmaceuticals Pte Ltd and developed in partnership with asthma experts, is a survey of asthma patients in Asia which aimed to assess patient attitudes and behaviours towards their disease. The survey was conducted with 2,467 people with asthma aged 18-50 across 8 Asian countries/regions. In order to take part in the survey, respondents must have received at least two prescriptions for their asthma in the past two years and also had to be active on social media.

About Asthma

Asthma is a chronic (long-term) inflammatory disorder of the airways which leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing. Asthma is a serious condition affecting over 70 million people in Asia. Patients with poorly managed asthma are at an increased risk of exacerbations, hospitalisation and death. Poorly managed asthma can also have a huge impact on a person’s quality of life and day-to-day activities.vi

About Mundipharma

The Mundipharma network of independent associated companies consists of privately owned companies and joint ventures covering the world’s pharmaceutical markets. These companies are committed to bringing to patients the benefits of pioneering treatment options in the core therapy areas of oncology, pain, respiratory and rheumatoid arthritis.

For further information please visit: www.mundipharma.com.sg.

Posters presented
Copies of the posters can be made available on request.

P-A-022 Awareness and usage of inhalers among patients with asthma: findings from REALISE Asia J.C. Hoet al. (2014)
Friday, 14 November, 2014 1:00 – 3:00 PM

P-A-023 Preferred sources of information on asthma: data from multinational survey of patients in Asia
A. David-Wang et al. (2014)
Friday, 14 November, 2014 1:00 – 3:00 PM

P-A-031 Differences in patient-perceptions and levels of asthma control across 8 Asian countries: data from the REALISE Asia survey
A.R. Muttalif et al. (2014)
Saturday, 15 November, 2014 1:00 – 3:00 PM

Oral presentations
Overview slides can be made available on request.

O-A-011 Identification of attitudinal clusters in patients with asthma: analysis from REALISE Asia
S.H. Cho et al. (2014)
Saturday, 15 November, 2014 8:30 – 8:40 AM

O-A-013 Discrepancy between patient-perception and guideline-defined asthma control in Asia: a survey of over 2400 patients
S.H. Cho et al. (2014)
Saturday, 15 November, 2014 8:50 – 9:00 AM

O-A-014 Patterns of hospitalization and healthcare utilization across attitudinal clusters: analysis from patient survey in Asia
D.W. Perng et al. (2014)
Saturday, 15 November, 2014 4:15 – 4:25 PM

Notes:

[1] The International Union Against Tuberculosis and Lung Disease. The Global Asthma Report 2011. Available from: http://www.globalasthmanetwork.org/publications/Global_Asthma_Report_2011.pdf . Last accessed on 13 November 2014.

[2] REcognise Asthma and LInk to Symptoms and Experience (REALISE™) Asia. REALISE™ Asia was conducted online, by phone and face-to-face with 2,467 people with asthma aged 18-50 in Mainland China, Hong Kong,South Korea, Taiwan, Malaysia, Indonesia, the Philippines and Singapore. It was sponsored by Mundipharma Pharmaceuticals Pte Ltd and developed in partnership with asthma experts.

[3] GINA-defined control status (iHARP index). http://iharp.org  Last accessed on 13 November 2014.

[4] S.H. Cho et al (2014). O-A-011, to be presented at APSR.

[5] D.W. Perng et al (2014). O-A-014, to be presented at APSR.

[6] Gold LS et al. Resp Med 2014; 108:271-7.

Photo – http://photos.prnasia.com/prnh/20141120/8521406798

Source: Mundipharma

Written by asiafreshnews

November 21, 2014 at 11:57 am

Posted in Healthcare